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Abstract
Background: The aims of the present study were first to detect MCID for WOMAC in a Moroccan population, and
second, to identify the best pre-treatment predictors on the change of health after treatment by non-specific, non-
steroidal anti-inflammatory drugs (NSAIDs), and to evaluate whether the predictors were dependent on the choice
of the response criterion.
Methods: The study involved 173 patients with osteoarthritis in whom primary care physicians decided to start
treatment with non-selective NSAIDs. Assessments at admission and after 6 weeks were conducted. In order to
determine the threshold levels associated with a definition of clinically important improvement, the receiver
operating characteristic method was used. Three different measures of response to a 6-week NSAIDs treatment
were used: one indirect measure (MCID in the total WOMAC score), one direct measure (transition question) and a
combination of both criteria.
Results: Eighty patients (46.3%) reported “a slightly better” general health status compared to that of 6 weeks
before NSAIDs treatment. The MCID proportion is a 16.0% reduction in WOMAC. The most stable pre-treatment
predictors on the improvement of health after treatment by NSAIDs were the absence of previous knee injury and
a high level of education.
Conclusions: In our data, a 16.0% reduction of the total WOMAC score from baseline was associated with the
highest degree of improvement on the transition scale category. This cut-off point had good accuracy, and should
be appropriate for use in the interpretation of clinical studies results, as well as in clinical care.
Background
Osteoarthritis (OA) is one of the most common disabil-
ities from which the elderly population suffers, and is
projected to be the fourth leading cause of disability
worldwide by the year 2020 [1]. A disability may be
characterized as the impaired performance of expected
socially defined life tasks, in a typical socio-cultural and
physical environment [2,3].
A comprehensive assessment of the patient’s health
status is gaining in importance, now that health care is
becoming increasingly evidence-based. As the growing
number of the elderly in industrial nations exerts addi-
tional pressure on the fiscal resources of health care sys-
tems, medical action within strict guidelines is in greater
demand [4-6]. One of the key issues for evidence-based
and cost-effective medicine is the detection and proof of
the effects of a particular intervention. In fact, the ability
of an instrument to detect such a small difference is
essential in order to quantify the minimal difference
that patients and their physicians consider clinically
important. The minimal clinically important difference
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ence in score that patients perceive as beneficial and
which would then mandate, in the absence of trouble-
some side effects and excessive costs, a change in the
patient’s management [7]. In particular, when a therapy
is ameliorative rather than curative, clinicians need to
know whether a small degree of symptom relief is
important or trivial from the patient’s perspective [8].
For the assessment of interventions in OA of the lower
extremities, the Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) is generally
recommended as the most sensitive, condition-specific
instrument [9-14].
Symptomatic treatments of OA consist of non-phar-
macological as well as pharmacological interventions,
including the use of non-steroidal anti-inflammatory
drugs (NSAIDs). A major goal of OA treatment is,
therefore, pain management to optimize algo-functional
features, and to improve the patient’sq u a l i t yo fl i f e .
NSAIDs reduce inflammation, alleviate pain, and main-
tain functional activity. Therefore, knowledge of predic-
tors and the identification of patients for whom the
probability of treatment success is high at the time of
assessment might facilitate the optimization of indivi-
dual programs. We are interested in identifying baseline
risk factors to help clinicians better identify which of
their patients evaluated for the first time are likely to
make future improvements.
The minimal clinically important difference for
WOMAC has not been studied in the Moroccan popu-
lation. Thus, the aims of the present study were first, to
detect MCID for WOMAC in a Moroccan population,
and second, to identify the best pre-treatment predictors
on the change of health after treatment by non-specific,
non-steroidal anti-inflammatory drugs (NSAIDs), and to
evaluate whether the predictors were dependent on the
choice of the response criterion.
Methods
Study design
The ethics committee of Al Ayachi University Hospital
approved the study protocol and all patients gave
informed written consent prior to their inclusion in the
study. This is an ancillary protocol to a prospective
non-randomized study that involved 173 patients with
OA in whom primary care physicians decided to start
treatment with non-selective NSAIDs. Data were col-
lected between January and May 2009 at Al Ayachi Uni-
v e r s i t yH o s p i t a l .T h es t u d ywas specifically designed
with inclusion and exclusion criteria that would yield a
study population representative of community-based
osteoarthritis patients. Eligible patients were aged 18
years or older; had osteoarthritis of the knee (meeting
American College of Rheumatology classification
criteria); had experienced at least moderate pain in the
worst-affected knee (a score of 30 mm or more on a
visual analogy scale (VAS) as assessed by the patient)
that was judged by the investigator to require treatment
with an anti-inflammatory agent to control arthritis
symptoms; and had a Functional Capacity Classification
of ranging from I to III [15]. Patients were excluded
from the study if they had an active gastrointestinal dis-
ease, a history of gastric or duodenal ulcer, gastrointest-
inal bleeding or ulcer perforation, cancer, serious
hepatic or renal diseases or any condition precluding
N S A I Dt h e r a p y ,p r e v i o u se x p o s u r et oi n v e s t i g a t i o n a l
coxibs and NSAIDs during the past 3 months, and con-
comitant use of corticosteroids, anticoagulants, or low
dose aspirin. Additional criteria for exclusion were
intra-articular corticosteroid or intra-articular hyaluronic
acid joint injection within 8 weeks before randomiza-
tion, a known allergy of indomethacin or diclofenac and
history of abuse use of alcohol or drug use within 1 year
before screening. Pregnant or breast-feeding women
were also not eligible. Patients meeting entry criteria
received either indomethacin (25 mg) 150 mg daily or
diclofenac (50 mg) 150 mg daily for 6 weeks. A clinical
evaluation was performed by the investigators at the
screening visit, and then again at 6 weeks.
Data collection and measurements
At baseline, we collected data related to socio demo-
graphic parameters such as age, the number of pregnan-
cies, the level of education, the existence of previous
knee injuries and the duration of disease. We asked
patients if they have a back pain (Yes/No), currently
smoking (Yes/No), and comorbidity (binary): presence
of at least 1 comorbid factor: ischemic heart disease,
hypertension, diabetes mellitus, renal disease (protei-
nuria or haematuria) or current cancer. The body mass
index (BMI) was calculated as body weight (kg)/height
(m
2). Knee height was measured on the right leg, using
a sliding broad-blade caliper, with the subject in the
seated position (see Figure 1) [16].
Western ontario and McMaster universities OA index
(WOMAC)
At baseline and after 6 weeks, patients were asked to
complete the Western Ontario and McMaster Universi-
ties OA Index (WOMAC). The WOMAC Osteoarthritis
Index is a disease-specific self-report questionnaire for
measurement of the symptoms of OA of the hips and
knees. It is reliable, valid, and sensitive to the changes in
the health status of patients with knee OA [13]. We
used the 3.1 Likert version with five response levels for
each item, representing different degrees of intensity
(none, mild, moderate, severe, or extreme) that were
scored from 0 to 4. The final score for the WOMAC
Hmamouchi et al. BMC Research Notes 2012, 5:58
http://www.biomedcentral.com/1756-0500/5/58
Page 2 of 9was determined by adding the aggregate scores for pain,
stiffness, and function. Scores range from 0 to 96 for
the total WOMAC where 0 represents the best health
status and 96 the worst possible status. The higher the
score, the poorer the function. Therefore, an improve-
ment was achieved by reducing the overall score. The
WOMAC has been translated and validated in Arabic
[17].
Transition scale
At the 6-week follow-up, patients had to compare their
general health status with that of 6 weeks earlier by the
transition questionnaire [18,19]. As described by the
authors, the question was “Please imagine how you
would have described your health status six weeks ago.
How do you feel in general today as compared to six
weeks earlier as far as your osteoarthritis is concerned?.”
T h ep o s s i b l er e p l i e sw e r e“much better,”“ slightly bet-
ter,”“ no change,”“ slightly worse,” or “much worse”.
This question was used as an anchor to establish the
MCID for patients receiving a NSAIDs treatment. We
used the answer “slightly better” to establish the MCID
for improvement.
The EuroQol
At baseline, patients were asked to complete the Medi-
cal Euroqol-5D (EQ-5D). It is a self-report questionnaire
that has two sections: The first part (EQ-5D) consists of
five questions covering the dimensions of mobility, self-
care, usual activities, pain/discomfort and anxiety/
depression, each with three levels of response. The
responses to the five items of the EQ-5D can be scored
using a utility-weighted algorithm [20] to create a single
index of quality of life ranging from -0.59 to 1, which
has been recommended for use in economic evaluation.
The second part (EQ-VAS) of the EuroQol consists of a
20 cm vertical visual analogue scale (VAS) ranging from
100 (best imaginable health state) to 0 (worst imaginable
health state). The EuroQol has been translated and vali-
dated in Arabic [21].
Radiography
Plain radiographs while standing on both legs and the
knee extended were taken with a horizontal X-ray beam,
using a Fuji FCR capsula XL on a 20 × 25 cm Fuji ST-
VI Computed Radiography (CR) imaging plate (Fuji
Medical Systems, Tokyo, Japan). Rotation of the foot
was adjusted to keep the second metatarsal bone parallel
to the X-ray beam. Images were downloaded into Digital
Imaging and Communication in Medicine (DICOM)
format files with a spatial resolution of 1584 × 2016 pix-
els (giving a pixel size of 0.01 mm) and 1024 gray levels.
Radiographs were evaluated for the presence of OA
defined by the Kellgren-Lawrence (KL) scale depicted in
the Atlas of Standard Radiographs of Arthritis (0 = nor-
mal, 1 = doubtful OA, 2 = minimal OA, 3 = moderate
OA, and 4 = severe OA) [22]. This scale is based on the
degree of osteophyte formation, joint space narrowing,
sclerosis, and joint deformity. The joint space width
(JSW) was measured on both the medial and lateral
aspect of each knee radiograph with electronic calipers.
The minimum vertical distance of JSW was chosen for
analysis. To avoid inter-observer variability, the same
examiner who was unaware of subject characteristics
performed all measurements.
Statistical methods
Calculation of the required sample size was based on
the assumption that indomethacin would reduce the
incidence of upper abdominal pain from 40 to 25%,
compared with diclofenac with a two-sided test, an
alpha level of 0.05, and a power of 80%. The statistical
analysis was performed in three steps. First, descriptive
statistics were calculated for baseline characteristics.
There were expressed as mean (standard deviation) or
medians (quartiles) for continuous variables and as per-
centage distributions for discrete variables. Normality of
t h ed a t aw a st e s t e dw i t hao n e - s a m p l eK o l m o g o r o v
Smirnov test to indicate the appropriateness of para-
metric testing. In the second step, the difference
between the mean effects measured by WOMAC of the
“slightly better” group and the “no change” group was
defined as the MCID of improvement. This method has
Figure 1 Body position for the measurement of knee height
(16). To measure knee height, the knee was bent to a 90° angle,
and the distance from the undersurface of the heel (the heel rested
on the caliper blade, and sandbags placed under the foot ensured
that the foot remained level with the heel) along the calf to the
anterior surface of the thigh over the femoral condyles (just
proximal to the kneecap) was measured.
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[18,23-25]
In order to determine the threshold levels associated
with our “ap r i o r i ” definition of clinically important
improvement of WOMAC, the receiver operating char-
acteristic (ROC) method, was used. Transition scale was
utilized as an external criterion to distinguish between
improved and non-improved patients. This method has
the advantage of synthesizing information on the sensi-
tivity and specificity for detecting improvement by an
external criterion [26,27]. The Area Under the ROC
curve (AUC) in this setting can be interpreted as the
probability of correctly identifying the improved patients
from non-improved. The area ranges from 0.5 (no accu-
racy in distinguishing improved from non-improved) to
1.0 (perfect accuracy) [26,27]. According to Swets et al.
[28], areas from 0.50 to about 0.70 represent poor accu-
racy, those from 0.70 and 0.90 are useful for some pur-
poses, and higher values represent high accuracy. From
the ROC curves we compute the optimal cut-off point,
corresponding with the maximum sum of sensitivity and
specificity. The mean effects measured by WOMAC of
the “slightly better” group and the “no change” group
was defined as the MCID of improvement on the
WOMAC global score [6,7,9,10].
The total WOMAC score at the 6-week follow-up
minus the score at baseline examination prior to the
treatment defined the effect measured by WOMAC.
The transition scale assessed the self-perceived change
at the 6-week follow up compared to baseline. To deter-
mine MCID, the WOMAC effects were related to the
transition replies. From the ROC curves we computed
the optimal cut-off point, using Youden’si n d e x .W e
estimated the MCID proportion (%), which is the pro-
portion of the sample with a change score exceeding the
MCID.
In the last step, three logistic regression models using
three definitions of the dependent variable responder
were developed. The first definition of response was the
MCID improvement (%) on the WOMAC global score.
The second definition of responder used the transition
scale. Patients who reported a slightly or a much better
health status on the transition scale were classified as
responders. The third definition of responder required
that responders showed an MCID in improvement on
the WOMAC global score and reported a health
improvement on the transition scale. Comparisons in
the change between three categories are carried out
using analyses of covariance (ANOVA) and we used
Bonferroni adjustment for each two samples categories
(womac and transition scale), (womac and both transi-
tion scale and womac), (transition scale and both transi-
tion scale and womac). Factors found to be significant
to the P < 0.25 level in univariate analysis because
variables close to significance in univariate analysis can
become significant in multivariate analysis, and variables
that were statistically significant predictors in one of the
other models, were included to the model and stayed in
the model. To examine whether disease severity is a pre-
dictor for response the WOMAC global baseline score
was included in the analysis with the dependent variable
“responder on the transition scale”. It was not included
in the analysis with the dependent variable “MCID
improvement (%) on the WOMAC global score”,
because this response definition was derived from the
relative change that adjusts for the expected high corre-
lation between absolute change and initial scores. Like-
wise, the WOMAC baseline score was not included in
the analysis with the dependent variable “MCID
improvement (%) on the WOMAC global score and
responder on the transition scale”. Univariate chi-square
tests were used to analyze the associations between
response and binary independent variables. Discrimina-
tion was assessed using the area under the receiver
operator characteristic curve (AUC) and calibration was
assessed using the Hosmer-Lemeshow goodness-of-fit
test for each model using the definitions of responder.
This article does not show the results about thresholds
All statistical analyses were performed using SPSS 13.0
for Windows. A significant P value of ≤ 0.05 was desig-
nated for all assessments.
Results
Socio-demographic and clinical characteristics of patients
(Table 1)
A total of 221 patients were screened and 173 were
included. The most common reason for non-inclusion
in the study was an inability to satisfy the clinical inclu-
sion criteria (n = 43). Five patients refused participation.
All patients completed the 6-weeks treatment period.
The baseline characteristics for 173 patients are shown
in Table 1. The mean (SD) age was 57.1 (10.1) years
and the mean (SD) BMI was 31 (4.8) kg/m2. The major-
ity was female (72.3%). Of the 173 patients enrolled, 26
(15.1%) reported previous knee injury and 61 (31.7%)
had no formal education.
MCID improvement of total WOMAC score
The mean changes in total WOMAC score (6-week fol-
low-up versus baseline) stratified by the transition scale,
are illustrated by bar charts in Figure 2. More positive
scores indicate greater improvement for WOMAC.
Eighty patients (46.3%) reported “a slightly better” gen-
eral health status with that of 6 weeks before NSAIDs
treatment and 31 (17.9%) answer that they have “much
better” improvement in quality of life. The group of
those who answered that they were slightly worse was
small (8.1%). The comparison of the change in total
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nificant difference (one-way analysis of variance, P <
0.001; bonferonni (difference between “slightly better”
group and “equal, worse” group)). The MCID propor-
tion is a 16.0% reduction in WOMAC. A raw change of
-15.5 (AUC 0.881 ± 0.011) and percent change of -16%
(AUC 0.889 ± 0.008) genarated from the ROC analyses
were optimal cut-off point associated with our definition
of MCID, namely the transition category of “slightly bet-
ter”. The sensitivity and specificity of the cut-off point
were 75% and 68%, respectively (Figure 3).
Responder definition
Univariate analysis
At baseline, a joint space width > 3.5 mm, a BMI > 31
kg/m
2, knee height > 49 cm, existence of previous knee
injuries, a high level of education and a number of preg-
nancies > 4 were associated with higher improvement in
WOMAC after 6 weeks.
Patients with the lowest level of the total WOMAC
s c o r ea tb a s e l i n ea n dt h el o w e s tK LG r a d eh a dt h e
greatest improvement in transition scale.
Patients with the lowest level of quality of life at base-
line (EQ-5D index and VAS) had the greatest improve-
ment in WOMAC and in the transition scale (Table 2).
Table 1 Characteristics of study participants
Number 173
Mean (SD) KS Z
Age (years) 57.1 (10.1) 0.874
Weight (kg) 76.2 (12.1) 0.875
Height (cm) 155.5 (5.4) 0.966
Body mass index (kg/m2) 31.1 (4.8) 0.770
Joint space width 3.2 (1.2) 0.910
EQ 5D index at baseline 0.2 (0.1) 0.984
EQ 5D after treatment 0.6 (0.3) 0.822
VAS EQ 5D at baseline 40 (18) 0.604
VAS EQ 5D after treatment 67 (18) 0.597
WOMAC at baseline 66 (20) 0.595
WOMAC after treatment 34 (17) 0.628
Median
(quartiles)
WOMAC raw change within transition scale at
endpoint
Much better 13 (12-22) 5.574*
Slightly better 28 (13-39) 3.765*
No change 17 (8-22) 5.318*
Slightly worse 1 (-8-11) 6.450*
Number of pregnancies 4(1-6) 1.366*
Duration of OA (month) 4 (2-10) 2.001*
N(%)
Female 125 (72.3) -
Existence of previous knee injuries 26 (15.1) -
Existence of back pain 58 (33.5) -
Co morbidities 101 (58.4) -
Smokers 12 (6.9) -
High level of education 61 (35.3) -
KS : Komorgorov Smirnov * P < 0.05
Normality of the continuous data was tested with the Komorgorov Smirnov
test
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Figure 2 Box plot of the WOMAC raw change (6-week follow up
vs. baseline) within transition scale at endpoint. Central line, median;
boxes, 25th to 75th percentiles; whiskers, 95% confidence intervals.
Figure 3 ROC curve of the WOMAC total score.Ap e r c e n t
change of -16% generated from the ROC analyses were optimal
cut-off point associated with our definition of MCID, namely the
transition category of “slightly better”. The sensitivity and specificity
of the cut-off point were 75% and 68% respectively.
Hmamouchi et al. BMC Research Notes 2012, 5:58
http://www.biomedcentral.com/1756-0500/5/58
Page 5 of 9Multivariate analysis
1. Responder definition “16% (MCID) improvement in
the WOMAC.” Statistically significant predictors for a
better outcome were high level of education (no formal
education/higher than no formal education) (OR = 3.77;
IC: 1.12-12.7) and absence of previous knee injury (OR =
4.55; IC: 1.46-14.8)
2. Responder definition “improvement on the transi-
tion scale” (data not shown). In this category no factor
was a statistically significant predictor for improvement
3. Responder definition “16% improvement in the
WOMAC and improvement on the transition scale.”
Statistically significant predictors for a better outcome
were absence of previous knee injury (OR = 10.27; IC:
2.08-50.6), low knee height (OR = 3.34; IC: 1.05-10.5)
and high level of education (OR = 3.7; IC: 1.01-13.41)
Comparison of prediction models with different responder
definitions
The model with the responder definition that required
responders to have “a 16% improvement in the WOMAC
and improvement on the transition scale” had the highest
value for the discrimination( A U C=0 . 8 4 ) .T h i sm o d e l
had also the best calibration of fit (PHL = 0.53) (Table 3).
The model with the restrictive responder definition that
required responders to have an improvement on the tran-
sitions scale had the lowest value for the discrimination
and calibration (AUC = 0.68, PHM = 0.25) data not
shown.
Discussion
In our study, a 16.0% reduction of the total WOMAC
score from baseline was associated with the “slightly bet-
ter” degree of improvement on the transition scale cate-
gory, and this cut-off point had good accuracy.
The concept of the minimal clinically important differ-
ence (MCID) has been proposed to refer to the smallest
difference in a score that is considered to be meaningful
or clinically important. In our study, the receiver operat-
ing characteristic (ROC) method was used. This method
has the advantage of synthesizing information on the
Table 2 Predictors of response to NSAIDs on the univariate level with three different definitions of responder
Independent variable 16% improvement in the WOMAC Transition Both criteria
OR IC 95% OR IC 95% OR IC 95%
Total WOMAC score at baseline - 0.43* 0.22-0.82 -
Age > 57 (years) 1.20 0.66-2.16 0.41 0.21-0.77 1.14 0.61-2.13
BMI > 31 (kg/m2) 1.79* 1.02-3.28 0.81 0.43-1.49 1.18 0.63-2.18
Joint space width > 3.5 mm 0.48* 0.23-0.98 1.59+ 0.76-3.21 0.61+ 0.28-1.30
Knee height > 49 cm 2.46* 1.18-5.13 0.75 0.36-1.51 1.05 0.49-2.25
KL Grade > 2 1.34 0.71-2.54 0.47* 0.23-0.97 1.26 0.68-2.45
Duration of OA > 4 (month) 1.14 0.51-2.56 0.75 0.39-1.72 1.38 0.59-3.21
Previous knee injuries 5.27* 1.83-15.38 2.25+ 0.86-5.85 3.92* 1.59-9.67
Co morbidities 0.71 0.38-1-28 0.67+ 0.35-1.21 0.60+ 0.32-1.13
Existence of back pain 1.77 0.15-19.9 18.2 0.51-24.5 3.39 0.31-38.2
High level of education 2.19* 1.15-4.19 0.63 0.33-1.21 1.72+ 0.91-3.25
Number of pregnancies > 4 2.48* 1.06-5.73 0.51+ 0.21-1.21 1.92+ 0.81-4.51
EQ index at baseline > 0.36 0.5+ 0.24-1 1.47 0.73-3.07 0.58+ 0.27-1.26
VAS EQ 5D at baseline > 40 0.21* 0.09-0.41 1.56+ 0.73-3.32 0.29* 0.12-0.71
+P < 0.25 * P < 0.05
Continuous variables were dichotomized by median as cut-off
Univariate analysis for the association between “Total WOMAC score at baseline” and the response definitions “16% improvement in the WOMAC” and “both criteria,”
respectively, are not represented because these response definitions adjust for the expected high correlation of WOMAC baseline score and the change of the WOMAC
Table 3 Comparison of predictors for OA treatment by NSAIDS with different definitions of responder
N (%) AUC P (HL) Predictors OR 95% CI P R2
16% improvement* 92 (53.2) 0.77 0.51 High level of education 3.77 1.12-12.7 0.03 0.34
No Previous knee injury 4.55 1.46-14.8 0.001
Both criteria+ 65 (37.6) 0.84 0.53 No Previous knee injury 10.27 2.08-50.6 0.004 0.47
Knee height 3.34 1.05-10.5 0.040
High level of education 3.7 1.01-13.41 0.047
*Patients with an MCID on the total WOMAC score (16% change)
+Patients who answered “slightly better” or “much better” to the health transition question and have an MCID on the total WOMAC score (16% change)
After adjusting of Age > 57 (years), Body mass index > 31 (kg/m2), Knee height > 49 cm; Joint space width > 3.5 mm; Existence of previous knee injuries; Co
morbidities; high level of education (no formal education vs. higher than no formal education); Number of pregnancies > 4; EQ 5D index at baseline > 0.36; VAS
EQ 5D at baseline > 40
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an external criterion.
In fact, the greatest difficulty in assessing the thresh-
old of symptomatic clinical importance is identifying an
appropriate reference standard [7] have asked indivi-
duals to introspect on life experiences and directly cali-
brate health status measures. Redelmeier et al. [8] took
the patients’ perspective and asked patients to evaluate
their health relative to others. In this study, we have
assessed thresholds by correlating scores on a health sta-
tus index to an external question: “transition scale.”
Several studies have shown that patients tended to
rate themselves as less disabled than each other [7,8]. In
our study, we found that the threshold of symptomatic
difference was smaller if patients were less disabled.
This optimistic bias in subjective comparison ratings
resembles several other cognitive phenomena. People
can adapt to their disabilities and become reluctant to
exchange their current problems for an alternative situa-
tion [8,29]. Together, these cognitive phenomena high-
light pitfalls of assessing a patient’sq u a l i t yo fl i f e ,b o t h
in research as well as in the doctor-patient relationship.
In our study, we estimated the MCID proportion (%)
whitch is the proportion of the sample with change
scores exceeding the MCID by the ROC analysis. In our
study, we found the same result of MCID using ROC
curve by correlating WOMAC scores to an external
question: “transition scale” that when calculating the dif-
ference between the before-after treatment of the
WOMAC total score (28 (change score of the slightly
better group)–1 7( c h a n g es c o r eo ft h eu n c h a n g e d
group) = 11 score points. 11/66 (66 = baseline
WOMAC score) = 16.7%). This is a coincidence that we
cannot explain.
The magnitude of the improvement seen in WOMAC
in our study after 6 weeks (16%) reflects a slightly
poorer condition than the one reported following a
similar methodology. Indeed, previous studies have
s h o w na n1 8 . 0 %r e d u c t i o ni nW O M A Ca st h ep e r c e n -
tage of patients with a MCID [30,31]. In our study, X-
ray examinations were performed at baseline, and
showed that 67.7% of patients presented higher than KL
grade 3. Furthermore, owing to the fact that above 30
mm on the VAS of pain was an inclusion criterion of
the study, the severity of OA in our cohort could be
considered as moderate to severe.
The best response definition in this study was a com-
bination of the transition question and percentage
change in WOMAC total score. This model had a better
ability to discriminate between responders and non-
responders than the other two models. In fact, to ask
the patient about a health transition is simple and intui-
tive, and patients with a very good or a very bad health
status can deteriorate or improve, respectively. But a
single transition question cannot be considered as a
stable measure. Taking into account the high mean age
of our samples and their low level of education, this
option would have made answering the questionnaire
far more complicated. Further studies has shown that
the MCID proportion is a reliable and valid measure,
and may be more stable than a single transition ques-
tion because of absence of optimistic bias [18,19].
Therefore, patients with baseline scores far above the
average (bad health) show higher improvements in the
change score compared to patients with a good health
status [18,31]. This is a well-known phenomenon: a sick
patient has higher potential to improve and the regres-
sion-to-the-mean effect. The more the patient’sc o n d i -
tion is serious, the more the improvement will be
important because the difference between the before-
after treatment will be considerable.
In our report, the most stable pre-treatment predictors
on the improvement of health after treatment by
NSAIDs in Moroccan osteoarthritis patients were the
absence of previous knee injury and a high level of edu-
cation, because they were confirmed across two logistic
regression models with different definitions of response
as the dependent variable.
A better outcome for highly educated patients was
found in studies that evaluated the outcome of joint
arthroplasty [31,32]. On the other hand, joint injury is a
well-known risk factor for knee OA and is associated
with increased severity of osteoarthritis [33-36]. This is
in line with our results. However, given that high level
of education and previous knee injury are historic
events, this raises the issue as to whether these are mod-
ifiable factors. Since this is obviously not the case, it
seems interesting to emphasize the therapeutic patient
education especially in patients with low level of
education.
The finding that presence of previous knee injuries is
associated with higher improvement in WOMAC total
in the univariate analysis but absence of previous knee
injuries is associated with higher improvement in
WOMAC total in the multivariate analysis may be con-
fusing. It is probably due to the existence of confound-
ing factors. When a variable is related to another
variable of the model, it may be obscured in univariate
analysis (not significant) and prove to be in multivariate
analysis. In our models, it may be the case of “previous
knee injury” and “joint pace width.”
Our study has some limitations. The patients in the
study were subjects for whom primary care physicians
identified the need to start treatment with NSAIDs.
This fact suggests strongly that these patients were
symptomatic at the time of the quality of life assess-
ment. Because OA may be characterized by phases of
flares and respite, the results we observed might be
Hmamouchi et al. BMC Research Notes 2012, 5:58
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tion of patients with OA. A possible limitation was that
we employed one transitional question, not one for each
domain, as it has been suggested [37]. This would have
increased the length of the questionnaire and increased
the rate of missing patients or items. Another question
that could be asked about our results is the absence of a
direct comparison with a control group. However, a
large set of complete data on socio-demographic vari-
ables was entered into the regression models, and in
addition, clinical measurements were taken.
Conclusions
In our data, a 16.0% reduction of the total WOMAC
score from baseline was associated with slightly better
improvement on the transition scale. This cut-off point
had good accuracy, and should be appropriate for use in
the interpretation of clinical studies results, as well as in
clinical care. The observation that patients with a high
level of education and an absence of previous knee
injury are the best responders to NSAIDs in Moroccan
osteoarthritis may be interesting to adopt and individua-
lize the treatment of patients who are, at present, less
likely to respond and to emphasize the therapeutic
patient education especially in patients with a low level
of education.
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